Rut Porta

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.

TL;DR: The BELIEF trial provides further evidence of benefit for the combined use of erlotinib and bevacizumab in patients with NSCLC harbouring activating EGFR mutations.

TL;DR: This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies.

TL;DR: EGCG is established as a potent and specific inhibitor of fatty acid synthesis (FASN), which may hold promise as a target-directed anti-cancer drug and may be free of the CPT-I related in vivo weight-loss that has been associated with C75.